manalikamdar

CD3xCD20 BsAb secondary CNS lymphoma (CUBIC Consortium) - 28 pts, most glofi, 64% active CNS dx, 64% prior CAR - active CNS: ORR 56% (CR 33%), CNS ORR 65% (CR 35%), 6-mo PFS 43% (CNS-PFS 53%) - no PD among pts achieving CR - responses in LM dx & post-CAR - 25% ICANS (incl G3-4) Encouraging activity as monotherapy (combo regimens no better). #lymsm nature.com/articles/s4140…

Congratulations to Dr. @majorajay and the L-THORs Lab on publication of one of the first studies of patient-reported time toxicity, focused on the time burden of various bispecific antibody therapies in FL and DLBCL. #lymsm cc @CUHematology @CUAnschutz @CUCancerCenter

Dr. @majorajay @CUHematology contributed to a multicenter study of nivo-AVD outcomes outside of the clinical trial setting, now published @Hemasphere_EHA. #lymsm pubmed.ncbi.nlm.nih.gov/42038745/

ctDNA data TRANSFORM 2L LBCL #lymsm - MRDneg = longer EFS at all timepoints - more pts achieved MRDneg with liso-cel v SOC (62% vs 38%) - among MRDneg pts: liso-cel ⬆️ EFS, PFS, DOR - MRD re-emergence by 1 yr: 0/20 liso-cel v 9/15 ASCT - ctDNA prognostic independent of PET Deeper/more durable remissions with CAR. Role for ctDNA + PET post-CAR? ascopubs.org/doi/pdf/10.120…

Spotlight on our @CULymphoma T-cell expert Dr. @BradHaverkos who will be at the @ISCL_Lymphomas conference in June 2026! #lymsm cc @CUHematology @CUCancerCenter @CUAnschutz

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Our @CULymphoma lead Dr. @mana1981 was just published @BloodPortfolio as part of a phase II trial of mosun/pola in relapsed/refractory mantle cell lymphoma. #lymsm #tcellrx ashpublications.org/blood/article/…

Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study ashpublications.org/blood/article/…

Our junior faculty Dr. @majorajay contributed to a @glow_nlphl multicenter study on outcomes of Stage IA NLPHL, now published @BloodAdvances. #lymsm #nlphlsm ashpublications.org/bloodadvances/…

DLBCL Rx is changing. Rapidly. Our latest @ASHbloodjournal review reflects on the shifting landscape and what comes next. Couldn’t have asked for a better partner than Nancy Bartlett, a true labor of love. ashpublications.org/blood/article-… @CULymphoma @CUHematology

Now published by Dr. @majorajay @CUHematology in @JNCI_Now: an original research article demonstrating earlier presentation and higher mortality of secondary colorectal cancers in childhood cancer survivors. #survivorship pubmed.ncbi.nlm.nih.gov/40838867/

Now published @ASTCT_Journal: Dr. @mana1981 contributed to an expert review on eligibility for CAR T-cell therapy, including for patients who do not meet clinical trial criteria. #tcellrx #lymsm pubmed.ncbi.nlm.nih.gov/41138816/

Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma ⁦@BloodAdvances⁩ American Society of Hematology ashpublications.org/bloodadvances/…

Our @CULymphoma faculty Dr. @majorajay had a #Tandem26 abstract featured @OncLive for a study about bispecific antibodies after CAR-T in relapsed/refractory mantle cell lymphoma. @CUHematology is part of the nationwide CUBIC bispecific consortium. #lymsm onclive.com/view/real-worl…

Many thanks to @OncLive for reviewing our #Tandem26 abstract on outcomes of CD20 bispecifics after CD19 CAR in R/R MCL, an analysis from the CUBIC Consortium. #lymsm #tcellrx Abstract link: astctjournal.org/article/S2666-… onclive.com/view/real-worl…

Our @CULymphoma lead Dr. @mana1981 was just published @TheLancet as part of the TRANSCEND FL trial of liso-cel in marginal zone lymphoma. #lymsm #tcellrx pubmed.ncbi.nlm.nih.gov/41692020/

Our newest @CULymphoma faculty Dr. @cduarte8490 presents aggressive lymphoma updates at @CUHematology 2026 Denver ASH Review. Dr. Duarte specializes in lymphoma with a focus on rare subtypes (PTLD, PCNSL). #lymsm

Packed house for our @CUHematology 2026 Denver ASH Review today! cc @CUAnschutz

In Vail this weekend co-chairing the @TotalHealthConf 2026 Best of Hematology with Dr. Erin Schwab. I'll be tweeting slides from the conference, so follow along! #leusm #mmsm #lymsm

Dr. @StevenBairMD @CUHematology presents at @TotalHealthConf 2026 Best of Hematology in Vail about targetable pathways in CLL. #lymsm